Organic Anion and Cation SLC22 "Drug'' Transporter (Oat1, Oat3, and Oct1) Regulation during Development and Maturation of the Kidney Proximal Tubule

被引:30
|
作者
Gallegos, Thomas F. [1 ]
Martovetsky, Gleb [2 ]
Kouznetsova, Valentina [3 ]
Bush, Kevin T. [1 ]
Nigam, Sanjay K. [1 ,3 ,4 ]
机构
[1] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Biomed Sci, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
来源
PLOS ONE | 2012年 / 7卷 / 07期
基金
美国国家卫生研究院;
关键词
HEPATOCYTE NUCLEAR FACTOR-4-ALPHA; RAT-KIDNEY; GENE-EXPRESSION; MOUSE KIDNEY; TARGETED DISRUPTION; FACTOR; 4-ALPHA; MICE; TRANSCRIPTION; MORPHOGENESIS; SYSTEMS;
D O I
10.1371/journal.pone.0040796
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Proper physiological function in the pre- and post-natal proximal tubule of the kidney depends upon the acquisition of selective permeability, apical-basolateral epithelial polarity and the expression of key transporters, including those involved in metabolite, toxin and drug handling. Particularly important are the SLC22 family of transporters, including the organic anion transporters Oat1 (originally identified as NKT) and Oat3 as well as the organic cation transporter Oct1. In ex vivo cultures of metanephric mesenchyme (MM; the embryonic progenitor tissue of the nephron) Oat function was evident before completion of nephron segmentation and corresponded with the maturation of tight junctions as measured biochemically by detergent extractability of the tight junction protein, ZO-1. Examination of available time series microarray data sets in the context of development and differentiation of the proximal tubule (derived from both in vivo and in vitro/ex vivo developing nephrons) allowed for correlation of gene expression data to biochemically and functionally defined states of development. This bioinformatic analysis yielded a network of genes with connectivity biased toward Hnf4 alpha (but including Hnf1 alpha, hyaluronic acid-CD44, and notch pathways). Intriguingly, the Oat1 and Oat3 genes were found to have strong temporal co-expression with Hnf4 alpha in the cultured MM supporting the notion of some connection between the transporters and this transcription factor. Taken together with the ChIP-qPCR finding that Hnf4 alpha occupies Oat1, Oat3, and Oct1 proximal promoters in the in vivo differentiating rat kidney, the data suggest a network of genes with Hnf4 alpha at its center plays a role in regulating the terminal differentiation and capacity for drug and toxin handling by the nascent proximal tubule of the kidney.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Distribution of the organic anion transporters Oat1 and Oat3 between renal membrane microdomains in obstructive jaundice
    Nosetto, Evangelina Cecilia
    Campagno, Romina Valeria
    Torres, Adriana Monica
    Brandoni, Anabel
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2020, 472 (06): : 711 - 719
  • [42] Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)
    Bokelmann, Kristin
    Brockmoeller, Juergen
    Tzvetkov, Mladen, V
    JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [43] Organic anion transporters 1 (OAT1) and OAT3 meditated the protective effect of rhein on methotrexate-induced nephrotoxicity
    Liu, Zhihao
    Jia, Yongming
    Wang, Changyuan
    Meng, Qiang
    Huo, Xiaokui
    Sun, Huijun
    Sun, Pengyuan
    Yang, Xiaobo
    Ma, Xiaodong
    Peng, Jinyong
    Liu, Kexin
    RSC ADVANCES, 2017, 7 (41): : 25461 - 25468
  • [44] Male-Dominant Activation of Rat Renal Organic Anion Transporter 1 (Oat1) and 3 (Oat3) Expression by Transcription Factor BCL6
    Wegner, Waja
    Burckhardt, Birgitta Christina
    Burckhardt, Gerhard
    Henjakovic, Maja
    PLOS ONE, 2012, 7 (04):
  • [45] Low doses of ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex
    Zlender, Vilim
    Breljak, Davorka
    Ljubojevic, Marija
    Flajs, Dubravka
    Balen, Daniela
    Brzica, Hrvoje
    Domijan, Ana-Marija
    Peraica, Maja
    Fuchs, Radovan
    Anzai, Naohiko
    Sabolic, Ivan
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 239 (03) : 284 - 296
  • [46] In vitro and in silico characterization of the transport of selected perfluoroalkyl carboxylic acids and perfluoroalkyl sulfonic acids by human organic anion transporter 1 (OAT1), OAT2 and OAT3
    Louisse, Jochem
    Pedroni, Lorenzo
    van den Heuvel, Jeroen J. M. W.
    Rijkers, Deborah
    Leenders, Liz
    Noorlander, Annelies
    Punt, Ans
    Russel, Frans G. M.
    Koenderink, Jan B.
    Dellafiora, Luca
    TOXICOLOGY, 2024, 509
  • [47] Deletion of Multispecific Organic Anion Transporter Oat1/Slc22a6 Protects against Mercury-induced Kidney Injury
    Torres, Adriana M.
    Dnyanmote, Ankur V.
    Bush, Kevin T.
    Wu, Wei
    Nigam, Sanjay K.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (30) : 26391 - 26395
  • [48] Organic cation transporters (OCT1, OCT2 and OCT3) and organic anion transporter (OAT3) mediate the uptake of duodenal ulcerogen cysteamine in intestinal epithelial cells (IEC-6)
    Khomenko, Tetyana
    Tolstanova, Ganna
    Chen, Longchuan
    Deng, Xiaoming
    Said, Hamid M.
    Szabo, Sander
    GASTROENTEROLOGY, 2007, 132 (04) : A575 - A576
  • [49] Knockout of Organic Anion Transporter OAT1 or OAT3 Induces Rightward Shift in Glucosuria Response Curve of SGLT2 Inhibitor Empagliflozin
    Fu, Yiling
    Breljak, Davorka
    Onishi, Akira
    Batz, Falk
    Patel, Rohit
    Huang, Winnie
    Song, Panai
    Mayoux, Eric W., Sr.
    Koepsell, Hermann
    Anzai, Naohiko
    Nigam, Sanjay K.
    Sabolic, Ivan
    Vallon, Volker
    Anzai, Naohiko
    Nigam, Sanjay K.
    Sabolic, Ivan
    Vallon, Volker
    DIABETES, 2017, 66 : A336 - A336
  • [50] Identification and functional characterization of variants of the human organic anion transporter, OAT3 (SLC22A8).
    Mangravite, L
    Erdman, A
    Giacomini, KM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P93 - P93